Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid-Reference-Cited by-同舟云学术

Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid

Published:2021-04 Issue: Volume:145 Page:115848
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Paschalis Eleftherios P.,Dempster David W.,Gamsjaeger Sonja,Rokidi Stamatia,Hassler Norbert^ORCID,Brozek Wolfgang,Chan-Diehl Faye W.,Klaushofer Klaus,Taylor Kathleen A.^ORCID

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference88 articles.

1. Cortical aging differences and fracture implications for the human femoral neck;Boyce;Bone,1993

2. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures;Marshall;Bmj,1996

3. Are patients with hip fractures more osteoporotic?;Cummings;Review of the evidence, Am J Med,1985

4. Biomechanics of fracture: is bone mineral density sufficient to assess risk?;McCreade;J. Bone Miner. Res.,2000

5. Corticosteroids and fractures: a close encounter of the third cell kind [editorial; comment];Manolagas;J. Bone Miner. Res.,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanical impact of regional structural deterioration and tissue-level compensation on proximal femur trabecular bone;Frontiers in Bioengineering and Biotechnology;2024-09-09

2. Injectable foam-like scaffolds release glucose oxidase-integrated metal–organic framework hybrids for diabetic bone defects;Applied Materials Today;2024-06

3. Bone Material Properties in Bone Diseases Affecting Children;Current Osteoporosis Reports;2023-10-28

4. Improvement of bone formation by bionic hydroxyapatite nanorod via the regulation of macrophage polarization;Journal of Materials Science & Technology;2023-02

5. Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values;Bone;2022-09